As Arab Spring Stabilizes, Hikma Sees Improved Results And Better Position
This article was originally published in PharmAsia News
Executive Summary
For a company like Hikma Pharmaceuticals PLC with over half of its business operating in the Middle East and North Africa, the first half of 2011 has been a challenging time. The political instability in many countries, especially in Egypt and Tunisia, has hurt Hikma's growth and profitability in the first six months
You may also be interested in...
PharmAsia News Favorite Stories From 2011
If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.
Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm
Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region
Hikma Looks To Be Partner Of Choice In MENA Region Via Acquisition Of Promopharm
Jordanian drug maker Hikma Pharmaceuticals PLC acquired 63.9% of Moroccan branded generics firm Promopharm SA Oct. 3 in a cash deal worth $111.2 million. The acquisition gives Hikma access to the fourth largest pharmaceutical market in the Middle East and North Africa, additional manufacturing capacity and capability, and a perhaps stronger claim to its goal of being a partner of choice for multinationals across the MENA region